Former AstraZeneca VP Joins Hansoh Pharma to Lead Metabolic Disorders and Channel Operations

(Source: PharmaResearch Network)

New Developments in Senior Management Changes in the Pharmaceutical Industry.

According toLatest Industry News，Following the official departure from AstraZeneca on April 21,Former Assistant Vice President of AstraZeneca China and Head of the Feiying Business – YanHua Guo has officially joined Hansoh Pharma as the Vice President of Channel Operation Development Department and Metabolism Business Unit.

According to the announcement,Yan Huaguo will be fully responsible for the business operations and team management of Hansoh Pharma's four major sectors: metabolism business, channel operations (including commerce, retail, and broad markets).

Yan Huaguo has a profound accumulation of 26 years in the pharmaceutical industry, holding a bachelor’s degree from Hohai University and a Bi-MBA degree from Peking University. Before joining Hansoh Pharma, he worked atJoined AstraZeneca in 2017, and was promoted to Assistant Vice President. He once fully helmed core businesses such as Flying Eagle and successfully completed the scale-up development of the business segment from scratch. He has held positions in well-known foreign enterprises such as Novo Nordisk and Eli Lilly, covering core therapeutic areas like endocrinology and cardiovascular, accumulating outstanding experience in sales, marketing, and government affairs management.

One of Yan Huaguo's core tasks after joining Hansoh isResponsible for the upcoming blockbuster product of the Metabolism Business Unit —— the dual-target weight loss injection "Olebipeptide (HS-20094)"". This is a GLP-1/GIP dual receptor agonist independently developed by Hansoh Pharma. As a once-weekly subcutaneous injection formulation, it is mainly used for long-term weight management in overweight or obese adults and patients with type 2 diabetes. Its pivotal Phase III clinical trial (HS-20094-301) has achieved positive results, with data showing that the average weight loss of participants was up to 19.3% from baseline after 48 weeks of treatment, and up to 97.2% of participants achieved a weight reduction of ≥5%."

Hansoh Pharma plans to submit a new drug marketing application in China soon and has reached a collaboration with Regeneron, granting it the rights to develop, manufacture, and commercialize the drug in regions outside mainland China.

Hansoh Pharma's 2025 financial report performance was equally impressive. According to the financial report data, the company's total revenue in 2025 reached 15 billion yuan, of which the sales of innovative drugs and collaborative products amounted to approximately 12.4 billion yuan, representing a year-on-year increase of 30.4%. Excluding collaborative income, the sales of innovative drugs accounted for 79.3% of the company’s total pharmaceutical revenue, up by 5.3 percentage points from the same period last year. This figure is significantly higher than that of the established innovative drug leader.Hengrui Pharma58.34% of innovative drugs highlights Hansoh Pharma's leading advantage in innovation transformation.

In this new role, Yan Huaguo will leverage the channel resources and refined operation experience accumulated at AstraZeneca to help Hansoh Pharma address the challenges of getting innovative drugs into hospitals and expanding grassroots coverage, in order to compete in the fiercely contested GLP-1 market.

Reference Source:

Pharmacokinetics